STOCK TITAN
  1. Home
  2. News
  3. ALPMY

Astellas Pharma Inc. - ALPMY STOCK NEWS

IMPACT
SENTIMENT
ALPMY : OTC
Astellas Submits New Drug Application for Zolbetuximab in Japan
IMPACT
SENTIMENT
ALPMY : OTC
Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430
IMPACT
SENTIMENT
ALPMY : OTC PFE : NYSE
Astellas Highlights Continued Delivery of Strong Cancer Portfolio and Pipeline at 2023 ASCO Annual Meeting
IMPACT
SENTIMENT
ALPMY : OTC
Astellas Announces Commitments to 3rd Phase of GHIT Fund Replenishment
IMPACT
SENTIMENT
ALPMY : OTC
Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field
IMPACT
SENTIMENT
ALPMY : OTC
Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause
IMPACT
SENTIMENT
ALPMY : OTC PFE : NYSE
XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide
IMPACT
SENTIMENT
PFE : NYSE ALPMY : OTC
XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide
IMPACT
SENTIMENT
ALPMY : OTC
Results from Astellas' Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet
clinical trial
IMPACT
SENTIMENT
ALPMY : OTC
CiRA, Kyoto University and Astellas Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
Stock ALPMY logo
Astellas Pharma Inc.

OTC:ALPMY

ALPMY Rankings

#575 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ALPMY Stock Data

Medicinal and Botanical Manufacturing
Manufacturing
Link
Pharmaceuticals: Other, Health Technology, Manufacturing, Medicinal and Botanical Manufacturing
Japan
Chuo Ku